PCN74 Long-Term Cost-Effectiveness of Nadofaragene Firadenovec and Oportuzumab Monatox for Treatment of Bacillus Calmette-Guerin (BCG)-Unresponsive, Non-Muscle Invasive Bladder Cancer (NMIBC)
Abstract
Authors
M. Joshi S.J. Atlas D.M. Rind M. Beinfeld A. McKenna S. Patel R.H. Chapman S. Pearson D. Touchette